TY - JOUR
T1 - The Future of Parkinson's Disease Research
T2 - A New Paradigm of Human Specific Investigation Is Necessary and Possible
AU - Cassotta, Manuela
AU - Geerts, Hugo
AU - Harbom, Lise
AU - Outeiro, Tiago F.
AU - Pediaditakis, Iosif
AU - Reiner, Orly
AU - Schildknecht, Stefan
AU - Schwamborn, Jens C.
AU - Bailey, Jarrod
AU - Herrmann, Kathrin
AU - Hogberg, Helena T.
N1 - Funding Information:
lates scientific findings on individuals (including de novo PD patients, unmedicated PD, prodromal, and at-risk patients, both with genetic and sporadic PD, and healthy volunteers). They collaborate with the research community to collect and distribute data resources. The Parkinson’s Progression Markers Initiative11, sponsored by the MJFF8, is an ongoing longitudinal observational study launched in 2010 that collects comprehensive clinical, imaging, and genetic data and biological samples, with more than 1,500 participants. This study is supported by industry partners and has built a robust database and biore-pository, which is made accessible to the research community to promote biomarker identification and validation as well as therapeutic development. Similarly, the Aligning Science Across Parkinson’s12 (ASAP) initiative is fostering collaboration and resources to better understand the underlying causes of PD by supporting open-access policy. More initiatives like these should be promoted.
Publisher Copyright:
© The Authors, 2022.
PY - 2022
Y1 - 2022
N2 - Parkinson's disease (PD) is a complex neurodegenerative condition with a multifactorial origin. To date, approaches to drug discovery for PD have resulted in symptomatic therapies for the motor manifestations and signs associated with neurodegeneration but have failed to identify preventive or curative therapies. This failure mainly originates from the persistence of major gaps in our understanding of the specific molecular basis of PD initiation and progression. New approach methodologies (NAMs) hold the potential to advance PD research while facilitating a move away from animal- based research. We report a workshop involving NAM experts in the field of PD and neurodegenerative diseases, who discussed and identified a scientific strategy for successful, human-specific PD research. We outline some of the most important human-specific NAMs, along with their main potentials and limitations, and suggest possible ways to overcome the latter. Key recommendations to advance PD research include integrating NAMs while accounting for multiple levels of complexity, from molecular to population level; learning from recent advances in Alzheimer's disease research; increasing the sharing of data; promoting innovative pilot studies on disease pathogenesis; and accessing philanthropic funding to enable studies using novel approaches. Collaborative efforts between different stakeholders, including researchers, clinicians, and funding agencies, are urgently needed to create a scientific roadmap and support a paradigm change towards effective, human-specific research for neurodegenerative diseases without animals, as is already happening in the field of toxicology.
AB - Parkinson's disease (PD) is a complex neurodegenerative condition with a multifactorial origin. To date, approaches to drug discovery for PD have resulted in symptomatic therapies for the motor manifestations and signs associated with neurodegeneration but have failed to identify preventive or curative therapies. This failure mainly originates from the persistence of major gaps in our understanding of the specific molecular basis of PD initiation and progression. New approach methodologies (NAMs) hold the potential to advance PD research while facilitating a move away from animal- based research. We report a workshop involving NAM experts in the field of PD and neurodegenerative diseases, who discussed and identified a scientific strategy for successful, human-specific PD research. We outline some of the most important human-specific NAMs, along with their main potentials and limitations, and suggest possible ways to overcome the latter. Key recommendations to advance PD research include integrating NAMs while accounting for multiple levels of complexity, from molecular to population level; learning from recent advances in Alzheimer's disease research; increasing the sharing of data; promoting innovative pilot studies on disease pathogenesis; and accessing philanthropic funding to enable studies using novel approaches. Collaborative efforts between different stakeholders, including researchers, clinicians, and funding agencies, are urgently needed to create a scientific roadmap and support a paradigm change towards effective, human-specific research for neurodegenerative diseases without animals, as is already happening in the field of toxicology.
UR - http://www.scopus.com/inward/record.url?scp=85135895917&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85135895917&partnerID=8YFLogxK
U2 - 10.14573/altex.2203161
DO - 10.14573/altex.2203161
M3 - Article
C2 - 35404466
AN - SCOPUS:85135895917
SN - 1868-596X
VL - 39
SP - 694
EP - 709
JO - ALTEX
JF - ALTEX
IS - 4
ER -